TY - JOUR
T1 - Haematological consequences of acute uncomplicated falciparum malaria
T2 - a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data
AU - The WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group
AU - Mansoor, Rashid
AU - Commons, Robert J.
AU - Douglas, Nicholas M.
AU - Abuaku, Benjamin
AU - Achan, Jane
AU - Adam, Ishag
AU - Adjei, George O.
AU - Adjuik, Martin
AU - Alemayehu, Bereket H.
AU - Allan, Richard
AU - Allen, Elizabeth N.
AU - Anvikar, Anupkumar R.
AU - Arinaitwe, Emmanuel
AU - Ashley, Elizabeth A.
AU - Ashurst, Hazel
AU - Asih, Puji B.S.
AU - Bakyaita, Nathan
AU - Barennes, Hubert
AU - Barnes, Karen I.
AU - Basco, Leonardo
AU - Bassat, Quique
AU - Baudin, Elisabeth
AU - Bell, David J.
AU - Bethell, Delia
AU - Bjorkman, Anders
AU - Boulton, Caroline
AU - Bousema, Teun
AU - Brasseur, Philippe
AU - Bukirwa, Hasifa
AU - Burrow, Rebekah
AU - Carrara, Verena I.
AU - Cot, Michel
AU - D’Alessandro, Umberto
AU - Das, Debashish
AU - Das, Sabyasachi
AU - Davis, Timothy M.E.
AU - Desai, Meghna
AU - Djimde, Abdoulaye A.
AU - Dondorp, Arjen M.
AU - Dorsey, Grant
AU - Drakeley, Chris J.
AU - Duparc, Stephan
AU - Espié, Emmanuelle
AU - Etard, Jean Francois
AU - Falade, Catherine
AU - Faucher, Jean Francois
AU - Filler, Scott
AU - Fogg, Carole
AU - Fukuda, Mark
AU - Sutanto, Inge
N1 - Funding Information:
RJC is funded by an Australian National Health and Medical Research (NHMRC) Emerging Leader Investigator Grant (1194702). RNP is a Wellcome Trust Senior Fellow in Clinical Science (200909). JAS is funded by an Australian NHMRC Senior Research Fellowship 1104975. NJW is a Wellcome Trust Principal Fellow. WWARN is funded by Bill and Melinda Gates Foundation and Exxon Mobil Foundation grants. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the paper. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. Methods: Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall ≥ 25% at day 3 and day 7. Results: A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0–19.7 g/dL) in Africa, 11.6 g/dL (range 5.0–20.0 g/dL) in Asia and 12.3 g/dL (range 6.9–17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to ≥ 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39–3.05], p < 0.001). Conclusions: In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.
AB - Background: Plasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia. Methods: Individual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin < 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall ≥ 25% at day 3 and day 7. Results: A total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0–19.7 g/dL) in Africa, 11.6 g/dL (range 5.0–20.0 g/dL) in Asia and 12.3 g/dL (range 6.9–17.9 g/dL) in South America. Moderately severe anaemia (Hb < 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age < 1 compared to ≥ 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39–3.05], p < 0.001). Conclusions: In patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.
KW - Antimalarials
KW - Artemisinin-based therapy
KW - Haemoglobin
KW - Non-artemisinin-based therapy
KW - Plasmodium falciparum
KW - Pooled analysis of individual patient data
KW - Severe anaemia
UR - http://www.scopus.com/inward/record.url?scp=85134025288&partnerID=8YFLogxK
U2 - 10.1186/s12916-022-02265-9
DO - 10.1186/s12916-022-02265-9
M3 - Article
C2 - 35249546
AN - SCOPUS:85134025288
SN - 1741-7015
VL - 20
JO - BMC Medicine
JF - BMC Medicine
IS - 1
M1 - 85
ER -